Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis.

F Fais1, C Tenca, G Cimino

  • 1Human Anatomy Section, Department of Experimental Medicine, University of Genoa, Italy. franco.fais@unige.it

Leukemia
|March 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent Advances in Human Natural Killer Cells.

International archives of allergy and immunology·2021
Same author

Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy.

Leukemia·2017
Same author

Therapeutic Strategies and Clinical Outcome in Papillary Thyroid Microcarcinoma: A Multicenter Observational Study.

European thyroid journal·2016
Same author

N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.

Leukemia·2012
Same author

Ligation of the lymphocyte homing receptor CD44 triggers T-helper and cytolytic functions of human T cells.

Cytotechnology·2012
Same author

T cell differentiation in the thymus.

Cytotechnology·2012
Same journal

Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.

Leukemia·2026
Same journal

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Leukemia·2026
Same journal

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026
Same journal

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same journal

Single-cell DNA methylation analysis uncovers epigenetic pathways in the transformation of MDS to AML.

Leukemia·2026
Same journal

PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.

Leukemia·2026
See all related articles

CD1d expression on childhood acute lymphoblastic leukemia (ALL) cells indicates a poor prognosis. However, these CD1d+ ALL cells may be a target for immunotherapy using alpha-galactosylceramide (alpha-GalCer).

Area of Science:

  • Immunology
  • Pediatric Oncology
  • Molecular Biology

Background:

  • Acute lymphoblastic leukemia (ALL) is a common childhood cancer with variable outcomes.
  • CD1d is a molecule presenting glycolipids to T cells, offering a potential immunotherapy target.
  • Alpha-galactosylceramide (alpha-GalCer) is a glycolipid recognized by CD1d-restricted T cells.

Purpose of the Study:

  • To investigate CD1d expression in pediatric B-cell precursor (BCP) ALL.
  • To determine the prognostic significance of CD1d expression in ALL.
  • To explore the therapeutic potential of targeting CD1d in ALL.

Main Methods:

  • Analysis of CD1d expression on 80 pediatric BCP ALL cases.
  • Correlation of CD1d expression with immunophenotype, cytogenetics, and patient age.

Related Experiment Videos

  • Assessment of CD1d+ ALL cells' ability to present alpha-GalCer to T cells.
  • Evaluation of T cell-mediated apoptosis and cytokine secretion.

    • Main Results:

    • CD1d was expressed on ALL cells in 15% of patients.
    • CD1d+ ALL was associated with infant leukemia, pro-B phenotype, and MLL/AF4 rearrangement.
    • Patients with CD1d+ ALL had significantly shorter overall survival.
    • CD1d+ ALL cells presented alpha-GalCer, inducing T cell-mediated apoptosis and cytokine secretion.

    Conclusions:

    • CD1d expression in pediatric ALL is linked to adverse prognosis.
    • CD1d+ ALL cells represent a potential therapeutic target for immunotherapy.
    • Targeting CD1d with alpha-GalCer may offer a novel treatment strategy for specific ALL subgroups.